RUNX3 and malignant colon neoplasm: Our findings demonstrated that the cytoplasmic distribution of RUNX3 in colon cancer cells under oxidative stress can be targeted for the development of novel therapy, as well as serving as potential biomarkers for the prediction of the occurrence of colon cancer.